Flow Cytometry in the Diagnosis of Canine B-Cell Lymphoma by Riondato, F. & Comazzi, S.
REVIEW
published: 19 March 2021
doi: 10.3389/fvets.2021.600986
Frontiers in Veterinary Science | www.frontiersin.org 1 March 2021 | Volume 8 | Article 600986
Edited by:
Steven E. Suter,




North Carolina State University,
United States
Arianna Miglio,
University of Perugia, Italy
William Kisseberth,






This article was submitted to
Comparative and Clinical Medicine,
a section of the journal
Frontiers in Veterinary Science
Received: 31 August 2020
Accepted: 26 February 2021
Published: 19 March 2021
Citation:
Riondato F and Comazzi S (2021)
Flow Cytometry in the Diagnosis of
Canine B-Cell Lymphoma.
Front. Vet. Sci. 8:600986.
doi: 10.3389/fvets.2021.600986
Flow Cytometry in the Diagnosis of
Canine B-Cell Lymphoma
Fulvio Riondato 1* and Stefano Comazzi 2
1Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Grugliasco, Italy, 2Dipartimento di Medicina Veterinaria,
Università degli Studi di Milano, Lodi, Italy
B cell lymphoma (BCL) is a heterogeneous group of lymphoid malignancies which
comprise the majority of canine lymphomas. Diffuse large B cell lymphoma is the most
common lymphoma subtype in dogs but other subtypes (e.g., marginal zone lymphoma,
follicular lymphoma, mantle cell lymphoma, and others) have been described. This review
aims to explore the use of flow cytometry to refine the diagnosis of canine BCL. Particular
emphasis will be given to the possible identification of peculiar immunotypes, putative
prognostic markers, staging and minimal residual disease.
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INTRODUCTION
Flow cytometry (FC) of fine needle aspirates has been increasingly applied as first-line analysis in
cases of suspected lymphoma in dogs. It is mainly used to investigate the immunophenotype of
the cells and refine the diagnosis obtained from other morphological diagnostic techniques such as
cytology and histopathology. In addition to the cell lineage definition, recent studies investigated
flow cytometric parameters with a potential clinical and diagnostic relevance. The present review is
aimed to summarize these aspects in B-cell lymphoma (BCL).
IDENTIFICATION OF B-CELL LINEAGE
Current histologic and cytologic classification of lymphomas (WHOandKiel updated, respectively)
(1, 2) requires the identification of the lineage of the cells. A possible correlation between updated
Kiel classification and WHO classification for BCLs according to (3) is reported in Table 1. FC
is one of the best available methods to define the immunophenotype of discrete cells in routine
diagnostics. The major advantages include the multiparametric approach and the availability of
a wider panel of antibodies compared to other techniques. This allows the description of the
antigenic pattern of cells and provides information about the lineage, differentiation/maturation,
activation, and other specific features. Unfortunately, only a few antibodies are commercially
available for the identification of B-cells in dogs. Common antibodies used to characterize B-
cells and their expected immunoreactivity in non-neoplastic cells are reported in Table 2. The
most widely used B-cell markers in FC are IgM, CD21, CD22, and CD79. Antibodies directly
conjugated with a fluorochrome are preferred in routine diagnostics; they allow a more effective
multicolor approach and a faster labeling protocol. Similarly, the staining procedure for membrane
epitopes (e.g., CD21, CD22, and IgM) is faster and better preserves the morphology of the
cells. In contrast, the detection of the transmembrane antigen CD79 requires an additional
cell permeabilization step to recognize the intracellular epitope. Monoclonal antibodies against
the alpha and beta heterodimers (CD79a and CD79b, respectively) have been developed and,
to the authors’ experience, they provide similar results. The combined evaluation of different
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TABLE 1 | Possible correlation between updated Kiel classification and WHO
classification for B-Cell Lymphomas according to (3).




Small lymphocytic B-cell CLL/small lymphocytic




Marginal zone Nodal MZL, extranodal MZL,
splenic MZL











Anaplastic/mediastinal Mediastinal BCL (DLBCL)
Burkitt type Burkitt lymphoma
Plasmacytoid –
Small cell NOS Mantle cell lymphoma?
BCL, B-cell lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell
lymphoma; MZL, marginal zone lymphoma; NOS, not otherwise specified.
markers may provide information on the maturation stage. For
instance, CD79 is detected in all stages of B-cell development,
IgM is expressed starting from an immature B-cell stage
while CD21 and CD22 are present only in mature B-
lymphocytes. Although currently not available on the market,
some monoclonal antibodies for canine CD20 have been
developed and validated in FC on clinical samples (4–6). Similar
to CD21 and CD22, CD20 is expressed by mature B cells, and
may be of aid in cases of ambiguous results with the former
markers. Other non-specific markers for B-cells may be added to
FC panels to discriminate their activation or maturation status.
Among these, the pan-leukocytic markers CD45 and CD18 are
generally expressed with lower intensity in B-cells than in other
leukocytes (7). CD25 is generally expressed by activated B-cells
and MHC II is expressed by mature B-cells. In humans, plasma
cells are CD38+, they retain CD79 but lose CD21 and IgM
expression. To date, no specific canine plasma cell marker is
commercially available. Further, there are no consistent data




A restricted expression of kappa or lambda light chain is
consistent with a B-cell clonal expansion and the evaluation
of the kappa/lambda ratio is the reference flow cytometric
method to diagnose a neoplastic proliferation of B-cells in
humans. Unfortunately, the kappa/lambda ratio is very low
TABLE 2 | Common antibodies used for the characterization of B-cells in dogs
and expected reactivities.
Target Antibody clones Reactivity
CD18 CA1.4E9 All leukocytes
CD19 4E9 B-cells, including early precursors
CD20 NCD1.2 Mature B-Lymphocytes
1E4
6C8
CD21 CA2.1D6 Mature B-lymphocytes
CD22 RFB4 Mature B-lymphocytes
CD25 P4A10 Activated lymphocytes
CD34 1H6 Precursors
CD45 YKIX716.13 All leukocytes
CA12.10C12
CD44 IM7 All hematopoietic cells
CD79a(cy) HM57 B-cells, including early precursors
CD79b(cy) AT107-2 B-cells, including early precursors
IgM polyclonal Immature/Mature B-cells
MHC II YKIX334.2 Monocytes, Histiocytes, Lymphocytes
CA2.1C12
Ki67 (nuclear) MIB-1 Proliferating cells
cy, cytoplasmic.
in the normal canine lymphoid populations (8) with lambda
chains strongly exceeding the kappa ones. Also, the majority of
canine BCL (19/23) showed a restricted expression of lambda
chain in a study using immunohistochemistry (1). Therefore,
although technically feasible, the kappa/lambda ratio has a poor
diagnostic significance to distinguish reactive and neoplastic B-
cell expansions in dogs.
In dogs, B cells generally represent a minority of the
population in non-neoplastic lymph nodes (9, 10), thus an
expansion of B cells suggests a possible BCL. However, there is no
consensus about a cutoff value to differentiate BCL and a reactive
proliferation in lymph nodes and variable criteria have been
adopted in different studies. In two studies, the mean percentage
of CD21+ cells in lymph node aspirates from clinically normal
dogs was 31.4% (95%, CI 24.7–38%) (11) and 33.9% (+/− 11.8%)
(12), respectively. Other studies adopted cutoff values of 60%
(9, 13) and 65% (14) to define a B-cell lineage in neoplastic lymph
nodes. However, a high percentage of residual non-neoplastic
T lymphocytes is often found in BCLs, and setting such high
cutoff values may significantly increase the rate of false non-
neoplastic results.
The evaluation of cell size in the lymph node aspirate may also
help to support the diagnosis of lymphoma since lymphocytes are
mostly small-sized in both normal and reactive lymph nodes (11)
(Figure 1). Cell size in FC is measured through Forward Scatter
(FSC) properties. FSC has a good correlation with the size of
the cell in cytology but not with the size of the nucleus, which
is the common morphologic feature used to describe neoplastic
cells as small, medium, or large. Coupling CD21 expression with
FSC greatly improves the ability of FC to differentiate BCLs from
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FIGURE 1 | Forward scatter (FSC) vs. side scatter (SSC) plots after doublet exclusion. (A) Reactive lymph node with few large-sized cells (P5); some granulocytes are
recognizable in the gate. (B) Large B-cell lymphoma with many large-sized cells (P5) easily recognizable even in the presence of a substantial residual population of
small lymphocytes.
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reactive lymph nodes. In a recent study, on different BCLs, most
lymphoma cases exhibited an FSC higher than 469U, a value
similar to FSC of residual T lymphocytes and higher than FSC
of normal B lymphocytes. Moreover, a median FSC higher than
720U (corresponding to about 1.6 times the one of residual T
lymphocytes) was adopted to define large-sized cases (15).
The most reliable way to confirm a neoplastic expansion is
the identification of one discrete population with aberrant or
abnormal antigenic pattern (pseudoclonality) (16). Aberrant co-
expression of T-cell or precursor markers (CD34) can sometimes
occur (9, 14, 17, 18). Diminished expression of CD79a is also
common (17) and CD21+ CD79− or CD21− CD79+ cases
are occasionally found (14, 18). However, the probability to
detect phenotypic aberrancies is strictly related to the number
and type of antibodies included in the panel. Again, the scarce
availability of specific antibodies for canine B-cells is the main
factor limiting the use of aberrant phenotypes as a major tool
to confirm clonality. In the personal experience of the authors,
and in agreement with some published papers (11, 19), large
BCLs commonly have a higher expression of CD21 if compared
to small non-neoplastic B lymphocytes (Figure 2). However, a
population with similar size and CD21 intensity was observed
in the spleen of healthy dogs (19). This finding suggests that
the large size of the cells and the upregulation of CD21 cannot
unequivocally differentiate neoplastic and non-neoplastic B-
lymphocytes.
FC cannot provide a definitive diagnosis of B-cell lymphoma
if there is no evidence of an obvious neoplastic population (i.e.,
phenotypic aberrances and/or a high percentage of cells with the
same phenotype) and in presence of a doubtful phenotype (i.e.,
absence or co-expression of T- and B-cell markers). In these cases,
histopathology and immunohistochemistry remain mandatory.
Additionally, PCR for Antigen Receptor Rearrangements (PARR)
analysis can help in achieving the correct diagnosis and define
lineage allocation (20); however it can be less sensitive and
accurate than FC to predict B and T phenotype (10).
REFINING THE DIAGNOSIS OF B-CELL
LYMPHOMA SUBTYPES
Although it may add some useful information to the diagnosis
of lymphoma and phenotyping (see below), FC is not currently
able to distinguish different types of BCL according to the WHO
classification system in dogs. Most BCLs diagnosed in dogs
are positive for both CD21 and CD79, while, CD21− CD79+
and CD21+ CD79− lymphomas are less common (14, 18).
Expression of T-cell markers in BCLs (lineage infidelity) may
occasionally occur (9, 10) but this aberrant expression has not
been correlated to any specific subtype. The cell size determined
by FC may be of aid in further classifying B-cell neoplasms:
as in cytology and histology, DLBCLs have large-sized cells
while follicular and diffuse small BCLs are characterized by
smaller cells (15). Unfortunately, most BCLs appear as medium
to large-sized and the identification of large cells does not
rule out subtypes other than DLBCL (15). In this context,
the determination of Ki67, a proliferation antigen, can help in
discriminating between high and low-grade forms (21). However,
in the author’s experience, histologically diagnosed MZLs may
present variable flow cytometric size (medium to large) and Ki67
values (indicative of both low and high-grade forms). Therefore,
it is not possible to differentiate large-sized high-Ki67 MZLs and
DLBCLs by flow cytometry alone (15, 22). This flow cytometric
presentation is consistent with a late stage of the disease with
more aggressive behavior (23) or, as described in humans, it
can represent a transformation of MZL in DLBCL. A similar
hypothesis has been formulated in dogs (24) and it is supported
by the similar molecular profile of MZL and DLBCL in this
species (25, 26).
Finally, no differences in the immunophenotype of different
subtypes of BCL were detected in one study (15). This limits the
current role of FC immunophenotype in the sub-classification of
B-cell lyphomas. However, the study included mostly DLBCL,
and possible phenotypic differences in other less frequent
lymphoma subtype should be further assessed.
REFINING THE PROGNOSIS OF B-CELL
LYMPHOMA
FC plays a leading role in defining two major characteristics of
lymphomas with possible impact on prognosis: cell lineage (B vs.
T) and staging (see below). Other FC features potentially related
to prognosis may derive from the evaluation of cell size, the
reactivity to some specific prognostic markers, and the evaluation
of the residual non-neoplastic cell population.
As previously described FSC values are indicative of small,
medium, or large cell lymphomas, although a correlation
between the flow cytometric and the morphologic information
(cytology and histology) has not been assessed so far. Of greater
importance, large flow cytometric cell size has been linked to
high-grade lymphoma subtypes (22) and a worse prognosis in
BCLs (27). A more specific evaluation of the grade of malignancy
is provided by Ki67 and S-phase values that may be determined
by FC in the lymph node at diagnosis. Cutoff values of 12.2
and 3.15%, respectively, were proposed to identify high-grade
forms (21, 28). Furthermore, the percentage of Ki67 stratifies
three prognostic groups in dogs affected by high-grade BCLs:
intermediate Ki67 values (20.1–40%) were associated with longer
relapse-free interval and survival time (median 428 and 866 days,
respectively) compared with low (<20%; median 159 and 42
days) and high values (>40%; median 100 and 173 days) in one
study (29).
Recently, additional prognostic markers have been
investigated by FC. Low levels of MHC II expression predicted
a poor outcome in BCLs in two studies (13, 27). However, this
result was not confirmed in a cohort of DLBCLs in a later study
(15). This discrepancy is likely due to the possible inclusion of
different BCL subtypes in the first studies. High levels of CD25
have been associated with a worse prognosis, resembling human
DLBCL (15, 30).
One of the main advantages of FC is the multiparametric
approach. Numerous parameters or markers can be evaluated on
every single cell at the same time. This feature allows an accurate
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FIGURE 2 | Flow cytometric presentation of a large B-cell lymphoma. (A) Forward scatter (FSC) vs. side scatter (SSC) plot after doublet exclusion showing two
populations of small- and large-sized cells. (B) FSC vs. CD21 plot of P4-gated cells showing higher CD21 expression on large cells (H6-UR) compared with small
B-lymphocytes (H6-UL).
and sensitive description of different subsets within a population.
The residual populations of non-neoplastic T lymphocytes are
easily identifiable in BCLs and they appear to play a role in the
progression of the neoplasm, thus suggesting an active influence
of the immune system on the tumor pathobiology and treatment
response. A higher percentage of regulatory T-cells (FoxP3+)
has proven to be an independent prognostic factor in BCLs (13)
and a recent study showed that higher percentages of CD5+ and
CD8+ lymphocytes and lower CD4+/CD8+ ratio at diagnosis
are associated with a lower likelihood of progression in dogs with
DLBCL treated with chemo-immunotherapy (31).
FC analysis of peripheral blood can be run to calculate the
lymphocyte-to-monocyte ratio. This ratio has been reported as an
independent prognostic factor and a value<=1.2 at the diagnosis
is associated with shorter time to progression and survival in dogs
with DLBCL treated with chemoimmunotherapy (32). Similar
cutoff (1.43) and results were obtained using a lymphocyte-to-
monocyte ratio calculated from hematology reports in another
study (18), as also described in human medicine (33, 34).
Finally, the multiparametric approach of FC is extremely
useful also to identify rarer cases of two coexisting neoplasms,
such as T-zone lymphoma and BCL (35–37). An example is
shown in Figure 3, where both BCL and TZL populations are
shown at diagnosis, at the end of CHOP chemotherapeutic
protocol, and at relapse of BCL.
STAGING B-CELL LYMPHOMA
FC is an excellent tool for staging lymphoma (i.e., to identify
neoplastic cell infiltration in different tissues), in particular
in fluid matrices including peripheral blood (PB) and bone
marrow (BM). The major advantage is that it allows examination
for populations with the same scatter and immunophenotypic
properties of the primary lesion. Good analytical performances
have been reported in the quantification of PB and BM
infiltration in dogs with large BCLs (38). Given the good accuracy
and precision reported and the differences in results provided
by operators in the evaluation of smears, FC appears a more
reliable method compared to microscope observation (39). A
sensitivity of 0.5 and 2% in blood and bone marrow, respectively,
and a diagnostic cutoff of 0.56 and 2.45% were identified for
flow cytometric detection of neoplastic large B-cells (38). These
values depend on the use of the currently available antibody
panel, therefore their accuracy would be likely improved with
the availability of new specific markers. Anyway, they appear
acceptable especially considering the prognostic threshold of
3% for BM infiltration in large BCLs that has been reported
in another study (40). In contrast, no PB cutoff values with
prognostic significance have been described for large BCLs so far.
The issue of staging BM infiltration is debated. Some
oncologists do not consider BM analysis mandatory to accurately
define the prognosis. This is probably because of the invasiveness
of the procedure and because bone marrow evaluation is
not considered necessary in absence of cytopenias, presence
of circulating blast cells, or other hematological alterations.
However, previous studies on DLBCL demonstrated that PB
and BM involvements are not directly correlated and it is
not possible to predict BM infiltration out of PB results
(23, 40). Furthermore, PB picture is not always predictive of
marrow involvement (41, 42), even though dogs with severe
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FIGURE 3 | Flow cytometric picture of a large B-cell lymphoma (LBCL) and a concurrent T-zone lymphoma (TZL) at presentation (row 1), end of CHOP chemotherapy
(row 2), and relapse of LBCL (row 3). Yellow gates (P6 and Q5-LR): LBCL cells. Green gates (R3 and Q5-UL): TZL cells. (A) plots (FSC vs. SSC): “morphologic”
presentation of the whole nodal population with gate (P5) activated for the analysis in plots (B,C); a prevalence of large-sized cells (higher FSC) is recognizable at
presentation and relapse while small and medium-sized cells are predominant at the end of chemotherapy. (B) plots (FSC vs. CD45): CD45 expression according to
cells size (FSC); the main population is represented by large CD45+ cells (P6, yellow) at presentation and relapse while it is made of medium CD45− cells (R3, green)
at the end of chemotherapy. (C) plots (CD45 vs. CD5): most of the events are CD45+CD5− (Q5-LR, yellow) at presentation and relapse while CD45-CD5+ cells
(Q5-UL, green) represent the majority of the population at the end of chemotherapy.
BM infiltration often show some hematological alterations
(thrombocytopenia, lymphocytosis, circulating neoplastic cells).
Thus, both tissues should be included in routine staging to
correctly stage the disease.
Regarding other BCL subtypes, a recent paper reported a
significant association between PB and BM infiltration and
prognosis in dogs affected with nodal MZL. Dogs with <30%
PB infiltration showed a significantly longer time to progression
while BM infiltration stratified cases in three groups (<1%;
1–20%; > = 20%) with different survival times (43).
EVALUATION OF MINIMAL RESIDUAL
DISEASE
The major role of FC in the follow-up of lymphoma patients
is related to the identification of the minimal residual disease
(MRD) in PB, BM, and lymph node at the end of the
chemotherapeutic protocol. In humans, MRD evaluation plays
a key role in the treatment plans of hematologic malignancies
and allows individualized tailoring of therapies, in particular for
leukemic patients (44). Similar to staging, FC can detect residual
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neoplastic cells in PB, BM, or lymph node looking for populations
with the same characteristics described at diagnosis, and thus it is
a useful tool to assess the efficacy of therapy.
A study evaluating MRD in lymph nodes, PB, and BM found
only a moderate agreement between FC and PARR at the end of
chemotherapy in dogs with DLBCL. Flow cytometric cutoff was
set at 1%. PARR was more sensitive than FC in predicting time to
relapse but only the combined interpretation of the two methods
was predictive of the overall survival (45). One of the reasons for
the only moderate concordance is the different sensitivity of the
two methods that in turn depends also on the threshold used
to define the positive and negative status. In this perspective, a
recent study showed a percentage >0.5% of large CD21+ cells
in lymph node to be predictive of a shorter time to relapse in
dogs with DLBCL in complete clinical remission (46). To the best
of our knowledge, no other studies have been published on the
prognostic significance of MRD in PB and BM so far.
FUTURE PERSPECTIVES
The development of new specific antibodies suitable for FC
and targeting more B-cell antigens may be useful to improve
the accuracy of the diagnosis of BCL and improve prognostic
abilities. In particular, specific antibodies recognizing plasma
cells (CD38) or immature B cells (CD20, CD19, CD10) labeled
with different fluorochromes are needed to be included in the
diagnostic panels.
The wide range of possible applications of FC makes it an
important tool for future developments in the field of canine
lymphoma. FC can contribute to the discovery of new therapeutic
targets and identification of new drugs with the ultimate goal
of more individualized therapies. Some examples include studies
focusing on specific markers such as PD-1 / PD-L1 (47, 48), c-kit
(49), or characterizing cell behavior such as the proliferative and
/or apoptotic response to differentmolecules (50–56), or aimed to
produce and characterize of new monoclonal antibodies (57, 58).
The diagnostic usefulness of flow cytometric analysis in
dogs affected by lymphoma is increasing. In this review, we
summarized recently reported flow cytometric indexes and
features with clinical significance for canine B-cell lymphomas.
To confirm and validate the diagnostic and prognostic role
of these parameters, larger multicentric prospective studies are
warranted. Collectively, they represent important milestones in
the exploration of the full power of flow cytometry in veterinary
oncology. They lay the foundation to understand why similar
lymphomas behave differently and to improve the ability to
differentiate prognosis among B-cell neoplasms and within a
single lymphoma subtype. Currently, flow cytometry has the
highest diagnostic value if combined with other morphologic
techniques such as cytology and/or histology. Its potential will be
expanded in the future but we believe the right way is to aim for
the result of fully integrated multidisciplinary (flow cytometry,
histology, cytology, genetic, molecular) lymphoma diagnosis.
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